TRT and Prostate Health: What the Evidence Actually Says

For decades, the standard medical advice was clear: if you care about your prostate, avoid testosterone therapy. The logic seemed intuitive — prostate cancer is androgen-sensitive, testosterone is an androgen, so more testosterone must mean more cancer risk. Right?

Wrong. This assumption has been systematically dismantled by modern research, yet the fear persists. It's one of the most consequential misconceptions in men's health, keeping thousands of men with symptomatic low testosterone from effective treatment.

Where the Fear Came From

The testosterone-prostate cancer hypothesis originated in a 1941 paper by Charles Huggins, who showed that castration reduced prostate cancer growth. The Nobel-winning insight was that prostate cancer is androgen-sensitive. The (incorrect) logical leap was that higher testosterone must therefore accelerate cancer growth.

For 50+ years, this was accepted medical dogma. Men with prostate cancer had their testosterone suppressed. Men worried about prostate cancer avoided TRT. It seemed to make sense.

The problem: Huggins' observations were about prostate cancer cells already in existence, not about the relationship between testosterone levels and the development of cancer in healthy prostate tissue. It's a critical distinction.

The Saturation Model — A Better Framework

The modern understanding of testosterone and prostate health is built around what's called the saturation model, developed largely through the work of Dr. Abraham Morgentaler at Harvard Medical School.

The saturation model proposes that prostate tissue has a finite capacity to respond to androgens. Once androgen receptors are saturated — which happens at relatively low testosterone levels — adding more testosterone has no additional stimulatory effect on prostate tissue.

Think of it like a sponge. Once the sponge is fully wet, pouring more water over it doesn't make it wetter — it just runs off. Prostate androgen receptors saturate at testosterone levels well below the normal physiologic range (around 250 ng/dL, perhaps lower). Adding testosterone above that saturation point doesn't drive more prostate cell activity.

This model explains something that confused researchers for years: prostate cancer rates don't track with testosterone levels across populations. Men with higher testosterone don't have higher prostate cancer rates. In fact, some studies show the opposite — lower testosterone is associated with more aggressive prostate cancer.

What the Research Actually Shows

Multiple large-scale analyses have examined TRT and prostate cancer risk in healthy men:

The Testosterone Trials (TTrials): This was the largest, most rigorous trial of TRT in older men with low testosterone. After one year of TRT, prostate cancer was detected in 1.0% of the testosterone group vs 0.8% of placebo. Not statistically significant — and importantly, the small difference was attributed to increased PSA screening in the testosterone group (more testing = more diagnoses, not more cancer).

Meta-analyses: A comprehensive 2010 meta-analysis of 19 controlled studies found no increased risk of prostate cancer or benign prostatic hyperplasia (BPH) with TRT. Updated analyses have consistently replicated this finding.

Hypogonadal men with high cancer risk: Perhaps most compelling, multiple studies have examined TRT in men with pre-existing prostate conditions — including treated prostate cancer — and found no increase in recurrence rates in carefully selected patients.

PSA Changes on TRT — Understanding What's Normal

When men start TRT, their PSA (Prostate-Specific Antigen) often rises modestly in the first few months. This alarms both patients and uninformed physicians, but there's important context:

PSA rises in response to testosterone stimulation of prostate tissue — but this is a predictable, limited effect. PSA typically increases and then plateaus within the first 3-6 months of therapy. A PSA that rises modestly and stabilizes is a normal response, not a red flag.

A PSA that continues to rise, rises rapidly (>0.75 ng/mL/year), or exceeds 4.0 ng/mL (or 3.0 in younger men) warrants further evaluation regardless of TRT status.

Marrow monitors PSA at baseline, 3 months, 6 months, and annually in all TRT patients. The baseline PSA is critically important — it establishes your individual reference point.

The Actual Prostate Risks of Low Testosterone

Here's the counterintuitive finding that most men don't know: low testosterone is associated with worse prostate outcomes in multiple ways.

BPH (Benign Prostatic Hyperplasia): Men with lower testosterone levels have been found in several studies to have worse BPH symptoms. The pathway isn't fully understood, but estrogen-to-testosterone ratio imbalance in hypogonadal men may contribute to prostate tissue changes that worsen urinary symptoms.

Prostate cancer aggressiveness: Several studies suggest that very low testosterone at the time of prostate cancer diagnosis is associated with more aggressive (higher Gleason grade) tumors. If anything, having physiologically normal testosterone may be protective against the worst cancer outcomes.

General health context: Low testosterone is a marker of poor metabolic health. The downstream effects — insulin resistance, obesity, inflammation — are themselves risk factors for cancer, including prostate cancer.

Monitoring on TRT — What Marrow Tracks

All Marrow TRT patients receive comprehensive monitoring:

Baseline (before starting): - Total and free testosterone - PSA (baseline is critical) - CBC (hematocrit, hemoglobin) - Metabolic panel - Estradiol

3-month check-in: - Testosterone levels (to assess dosing) - PSA - Hematocrit (TRT can increase red blood cell production) - Estradiol

6-month and annual: - Full panel repeat - Digital rectal exam (DRE) for men 40+ - Symptom review

A PSA that doubles, rises sharply, or crosses age-specific thresholds triggers additional workup — but in isolation, a small early rise is expected and monitored, not feared.

The Bottom Line

The fear that testosterone therapy causes prostate cancer is not supported by current evidence. It was based on a flawed extrapolation from early oncology research that has been systematically challenged by decades of subsequent study.

What the evidence shows instead: physiologically normal testosterone levels don't drive prostate cancer development in healthy men. The saturation model explains why — prostate androgen receptors are fully occupied at low testosterone levels, so additional testosterone has no additional stimulatory effect.

If you've been told you can't do TRT because of your prostate, the evidence deserves a second look. The calculus of risks and benefits may look very different from what you've been told.